Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial
Publication
, Journal Article
Hurwitz, H; Uppal, N; Wagner, SA; Bendell, J; Thaddeus, BJ; Wade, S; Nemunaitis, J; Stella, P; Pipas, JM; Wainberg, Z; Manges, R; Garrett, W ...
Published in: Annals of Oncology
June 1, 2014
Duke Scholars
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
June 1, 2014
Volume
25
Start / End Page
ii115
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Hurwitz, H., Uppal, N., Wagner, S. A., Bendell, J., Thaddeus, B. J., Wade, S., … Sandor, V. (2014). Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Annals of Oncology, 25, ii115. https://doi.org/10.1093/annonc/mdu193.26
Hurwitz, H., N. Uppal, S. A. Wagner, J. Bendell, B. J. Thaddeus, S. Wade, J. Nemunaitis, et al. “Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial.” Annals of Oncology 25 (June 1, 2014): ii115. https://doi.org/10.1093/annonc/mdu193.26.
Hurwitz H, Uppal N, Wagner SA, Bendell J, Thaddeus BJ, Wade S, et al. Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Annals of Oncology. 2014 Jun 1;25:ii115.
Hurwitz, H., et al. “Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial.” Annals of Oncology, vol. 25, June 2014, p. ii115. Scopus, doi:10.1093/annonc/mdu193.26.
Hurwitz H, Uppal N, Wagner SA, Bendell J, Thaddeus BJ, Wade S, Nemunaitis J, Stella P, Pipas JM, Wainberg Z, Manges R, Garrett W, Hunter D, Clark J, Leopold L, Levy R, Sandor V. Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Annals of Oncology. 2014 Jun 1;25:ii115.
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
June 1, 2014
Volume
25
Start / End Page
ii115
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis